Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1186/1476-511X-10-126 http://hdl.handle.net/11449/7163 |
Resumo: | Background: Previous work showed that daily ingestion of an aqueous soy extract fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus 416, supplemented or not with isoflavones, reduced the total cholesterol and non-HDL-cholesterol levels, increased the high-density lipoprotein (HDL) concentration and inhibited the raising of autoantibody against oxidized low-density lipoprotein (ox-LDL Ab) and the development of atherosclerotic lesions.Objective: The aim of this study was to characterize the fecal microbiota in order to investigate the possible correlation between fecal microbiota, serum lipid parameters and atherosclerotic lesion development in rabbits with induced hypercholesterolemia, that ingested the aqueous soy extract fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus 416.Methods: The rabbits were randomly allocated to five experimental groups (n = 6): control (C), hypercholesterolemic (H), hypercholesterolemic plus unfermented soy product (HUF), hypercholesterolemic plus fermented soy product (HF) and hypercholesterolemic plus isoflavone-supplemented fermented soy product (HIF). Lipid parameters and microbiota composition were analyzed on days 0 and 60 of the treatment and the atherosclerotic lesions were quantified at the end of the experiment. The fecal microbiota was characterized by enumerating the Lactobacillus spp., Bifidobacterium spp., Enterococcus spp., Enterobacteria and Clostridium spp. populations.Results: After 60 days of the experiment, intake of the probiotic soy product was correlated with significant increases (P < 0.05) on Lactobacillus spp., Bifidobacterium spp. and Enterococcus spp. and a decrease in the Enterobacteria population. A strong correlation was observed between microbiota composition and lipid profile. Populations of Enterococcus spp., Lactobacillus spp. and Bifidobacterium spp. were negatively correlated with total cholesterol, non-HDL-cholesterol, autoantibodies against oxidized LDL (ox-LDL Ab) and lesion size. HDL-C levels were positively correlated with Lactobacillus spp., Bifidobacterium spp., and Enterococcus spp. populations.Conclusion: In conclusion, daily ingestion of the probiotic soy product, supplemented or not with isoflavones, may contribute to a beneficial balance of the fecal microbiota and this modulation is associated with an improved cholesterol profile and inhibition of atherosclerotic lesion development. |
id |
UNSP_68beb1ef6eb3ae379ba7ec18c3114f2f |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/7163 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal modelprobioticsEnterococcus faecium CRL 183fecal microbiotalipid parametersBackground: Previous work showed that daily ingestion of an aqueous soy extract fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus 416, supplemented or not with isoflavones, reduced the total cholesterol and non-HDL-cholesterol levels, increased the high-density lipoprotein (HDL) concentration and inhibited the raising of autoantibody against oxidized low-density lipoprotein (ox-LDL Ab) and the development of atherosclerotic lesions.Objective: The aim of this study was to characterize the fecal microbiota in order to investigate the possible correlation between fecal microbiota, serum lipid parameters and atherosclerotic lesion development in rabbits with induced hypercholesterolemia, that ingested the aqueous soy extract fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus 416.Methods: The rabbits were randomly allocated to five experimental groups (n = 6): control (C), hypercholesterolemic (H), hypercholesterolemic plus unfermented soy product (HUF), hypercholesterolemic plus fermented soy product (HF) and hypercholesterolemic plus isoflavone-supplemented fermented soy product (HIF). Lipid parameters and microbiota composition were analyzed on days 0 and 60 of the treatment and the atherosclerotic lesions were quantified at the end of the experiment. The fecal microbiota was characterized by enumerating the Lactobacillus spp., Bifidobacterium spp., Enterococcus spp., Enterobacteria and Clostridium spp. populations.Results: After 60 days of the experiment, intake of the probiotic soy product was correlated with significant increases (P < 0.05) on Lactobacillus spp., Bifidobacterium spp. and Enterococcus spp. and a decrease in the Enterobacteria population. A strong correlation was observed between microbiota composition and lipid profile. Populations of Enterococcus spp., Lactobacillus spp. and Bifidobacterium spp. were negatively correlated with total cholesterol, non-HDL-cholesterol, autoantibodies against oxidized LDL (ox-LDL Ab) and lesion size. HDL-C levels were positively correlated with Lactobacillus spp., Bifidobacterium spp., and Enterococcus spp. populations.Conclusion: In conclusion, daily ingestion of the probiotic soy product, supplemented or not with isoflavones, may contribute to a beneficial balance of the fecal microbiota and this modulation is associated with an improved cholesterol profile and inhibition of atherosclerotic lesion development.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)São Paulo State Univ, Dept Food & Nutr, Sch Pharmaceut Sci, Araraquara, SP, BrazilUniv São Paulo, Dept Clin & Toxicol Anal, Sch Pharmaceut Sci, São Paulo, BrazilSão Paulo State Univ, Dept Clin Anal, Sch Pharmaceut Sci, Araraquara, SP, BrazilSão Paulo State Univ, Dept Food & Nutr, Sch Pharmaceut Sci, Araraquara, SP, BrazilSão Paulo State Univ, Dept Clin Anal, Sch Pharmaceut Sci, Araraquara, SP, BrazilBiomed Central Ltd.Universidade Estadual Paulista (Unesp)Universidade de São Paulo (USP)Cavallini, Daniela Cardoso Umbelino [UNESP]Suzuki, Juliana Y. [UNESP]Abdalla, Dulcineia S. P.Vendramini, Regina Célia [UNESP]Pauly-Silveira, Nadiege D. [UNESP]Roselino, Mariana N. [UNESP]Pinto, Roseli A. [UNESP]Rossi, Elizeu Antonio [UNESP]2014-05-20T13:23:39Z2014-05-20T13:23:39Z2011-07-29info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article9application/pdfhttp://dx.doi.org/10.1186/1476-511X-10-126Lipids In Health and Disease. London: Biomed Central Ltd., v. 10, p. 9, 2011.1476-511Xhttp://hdl.handle.net/11449/716310.1186/1476-511X-10-126WOS:000294599000001WOS000294599000001.pdf76419792878504893242858535763793Web of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengLipids in Health and Disease2.663info:eu-repo/semantics/openAccess2024-06-21T15:18:45Zoai:repositorio.unesp.br:11449/7163Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-06-21T15:18:45Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model |
title |
Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model |
spellingShingle |
Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model Cavallini, Daniela Cardoso Umbelino [UNESP] probiotics Enterococcus faecium CRL 183 fecal microbiota lipid parameters |
title_short |
Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model |
title_full |
Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model |
title_fullStr |
Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model |
title_full_unstemmed |
Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model |
title_sort |
Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model |
author |
Cavallini, Daniela Cardoso Umbelino [UNESP] |
author_facet |
Cavallini, Daniela Cardoso Umbelino [UNESP] Suzuki, Juliana Y. [UNESP] Abdalla, Dulcineia S. P. Vendramini, Regina Célia [UNESP] Pauly-Silveira, Nadiege D. [UNESP] Roselino, Mariana N. [UNESP] Pinto, Roseli A. [UNESP] Rossi, Elizeu Antonio [UNESP] |
author_role |
author |
author2 |
Suzuki, Juliana Y. [UNESP] Abdalla, Dulcineia S. P. Vendramini, Regina Célia [UNESP] Pauly-Silveira, Nadiege D. [UNESP] Roselino, Mariana N. [UNESP] Pinto, Roseli A. [UNESP] Rossi, Elizeu Antonio [UNESP] |
author2_role |
author author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (Unesp) Universidade de São Paulo (USP) |
dc.contributor.author.fl_str_mv |
Cavallini, Daniela Cardoso Umbelino [UNESP] Suzuki, Juliana Y. [UNESP] Abdalla, Dulcineia S. P. Vendramini, Regina Célia [UNESP] Pauly-Silveira, Nadiege D. [UNESP] Roselino, Mariana N. [UNESP] Pinto, Roseli A. [UNESP] Rossi, Elizeu Antonio [UNESP] |
dc.subject.por.fl_str_mv |
probiotics Enterococcus faecium CRL 183 fecal microbiota lipid parameters |
topic |
probiotics Enterococcus faecium CRL 183 fecal microbiota lipid parameters |
description |
Background: Previous work showed that daily ingestion of an aqueous soy extract fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus 416, supplemented or not with isoflavones, reduced the total cholesterol and non-HDL-cholesterol levels, increased the high-density lipoprotein (HDL) concentration and inhibited the raising of autoantibody against oxidized low-density lipoprotein (ox-LDL Ab) and the development of atherosclerotic lesions.Objective: The aim of this study was to characterize the fecal microbiota in order to investigate the possible correlation between fecal microbiota, serum lipid parameters and atherosclerotic lesion development in rabbits with induced hypercholesterolemia, that ingested the aqueous soy extract fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus 416.Methods: The rabbits were randomly allocated to five experimental groups (n = 6): control (C), hypercholesterolemic (H), hypercholesterolemic plus unfermented soy product (HUF), hypercholesterolemic plus fermented soy product (HF) and hypercholesterolemic plus isoflavone-supplemented fermented soy product (HIF). Lipid parameters and microbiota composition were analyzed on days 0 and 60 of the treatment and the atherosclerotic lesions were quantified at the end of the experiment. The fecal microbiota was characterized by enumerating the Lactobacillus spp., Bifidobacterium spp., Enterococcus spp., Enterobacteria and Clostridium spp. populations.Results: After 60 days of the experiment, intake of the probiotic soy product was correlated with significant increases (P < 0.05) on Lactobacillus spp., Bifidobacterium spp. and Enterococcus spp. and a decrease in the Enterobacteria population. A strong correlation was observed between microbiota composition and lipid profile. Populations of Enterococcus spp., Lactobacillus spp. and Bifidobacterium spp. were negatively correlated with total cholesterol, non-HDL-cholesterol, autoantibodies against oxidized LDL (ox-LDL Ab) and lesion size. HDL-C levels were positively correlated with Lactobacillus spp., Bifidobacterium spp., and Enterococcus spp. populations.Conclusion: In conclusion, daily ingestion of the probiotic soy product, supplemented or not with isoflavones, may contribute to a beneficial balance of the fecal microbiota and this modulation is associated with an improved cholesterol profile and inhibition of atherosclerotic lesion development. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-07-29 2014-05-20T13:23:39Z 2014-05-20T13:23:39Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1186/1476-511X-10-126 Lipids In Health and Disease. London: Biomed Central Ltd., v. 10, p. 9, 2011. 1476-511X http://hdl.handle.net/11449/7163 10.1186/1476-511X-10-126 WOS:000294599000001 WOS000294599000001.pdf 7641979287850489 3242858535763793 |
url |
http://dx.doi.org/10.1186/1476-511X-10-126 http://hdl.handle.net/11449/7163 |
identifier_str_mv |
Lipids In Health and Disease. London: Biomed Central Ltd., v. 10, p. 9, 2011. 1476-511X 10.1186/1476-511X-10-126 WOS:000294599000001 WOS000294599000001.pdf 7641979287850489 3242858535763793 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Lipids in Health and Disease 2.663 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
9 application/pdf |
dc.publisher.none.fl_str_mv |
Biomed Central Ltd. |
publisher.none.fl_str_mv |
Biomed Central Ltd. |
dc.source.none.fl_str_mv |
Web of Science reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1803045311982075904 |